PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
Explore this paper's citation graph
Summary
Four NSCLC patients with PD-L1 tumor proportion score ≥50% and good performance status, sharing high tumor burden including serosal involvement achieve major clinical and radiological response to pembrolizumab-chemotherapy combination, proving the feasibility and effectiveness of salvage chemo-immunotherapy in pembrology-refractory NSCLc patients.
- Type
- article
- Published
- 2021-02-03
- Cited by
- 6
- References
- 14
- OpenAlex
- https://openalex.org/W3127980980
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:231788847
Keywords
Pembrolizumab, Medicine, Immunotherapy, Refractory (planetary science), Internal medicine
References
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
- Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
- Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors
- Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
- Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer
- Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
- First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
- Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
- Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
- Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
- Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Cited by
- Cemiplimab: a new option for the treatment of non-small-cell lung cancer.
- PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
- High tumor burden in patients with non-small-cell lung cancer: a Delphi survey among Spanish oncologists.
- Radiomics nomogram for predicting chemo-immunotherapy efficiency in advanced non-small cell lung cancer
- Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50%
Related papers
- UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS
- P16.05 Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
- Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
- AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
- The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
- Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy